Navidea to Hold Conference Call to Provide Investor Update on Status of Ongoing Corporate Events
January 27 2017 - 4:59PM
Business Wire
Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced
that management will hold an audio webcast conference call on
Tuesday, January 31, 2017 at 4:30 p.m. to provide investor update
on status of ongoing corporate events. A business update will
follow the closing of the Cardinal Health transaction.
Investors and the public are invited to access the live audio
webcast through the link below. Participants are encouraged to
log-in and or/dial-in fifteen minutes before the conference begins.
The webcast replay is expected to be available on our investor
website, http://ir.navidea.com, approximately two to four hours
after the live event.
Event: Navidea Biopharmaceuticals Business Update
Call Date/Time: January 31, 2017; 4:30 p.m. ET
Webcast Link:
http://edge.media-server.com/m/p/ws822tj6/lan/en
Dial-In Number – US: (855) 897-5884 Dial-In Number –
Int’l: (720) 634-2940 Conference ID Number: 63292587
Replay:
A webcast replay will be available on the
Investor Relations section of our website at http://ir.navidea.com
for 30 days.
About Navidea
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a
biopharmaceutical company focused on the development and
commercialization of precision immunodiagnostic agents and
immunotherapeutics. Navidea is developing multiple
precision-targeted products and platforms including Manocept™ and
NAV4694 to help identify the sites and pathways of undetected
disease and enable better diagnostic accuracy, clinical
decision-making, targeted treatment and, ultimately, patient care.
Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s
first commercial product from the Manocept platform, was approved
by the FDA in March 2013 and in Europe in November 2014. The
development activities of the Manocept immunotherapeutic platform
will be conducted by Navidea in conjunction with its subsidiary,
Macrophage Therapeutics. Navidea’s strategy is to deliver superior
growth and shareholder return by bringing to market novel products
and advancing the Company’s pipeline through global partnering and
commercialization efforts. For more information, please visit
www.navidea.com.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170127005722/en/
Investors & MediaNavidea
BiopharmaceuticalsJed Latkin, COO & CFO,
614-973-7490jlatkin@navidea.com
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Aug 2024 to Sep 2024
Navidea Biopharmaceuticals (AMEX:NAVB)
Historical Stock Chart
From Sep 2023 to Sep 2024